| Field | Specification |
|---|---|
| Target | |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C18H28NO4P |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Dimemorfan phosphate is a sigma 1 receptor agonist used as an antitussive. It is supplied as a white to off-white solid (C18H28NO4P, MW 353.39) at 99.94% purity.
Physical & Chemical Properties
| CAS Number | 36304-84-4 |
|---|---|
| Molecular Formula | C18H28NO4P |
| Molecular Weight | 353.39 g/mol |
| Purity | 99.94% |
| Appearance | Solid |
| Color | White to off-white |
| SMILES | O=P(O)(O)O.CN1[C@](CC2=CC=C(C)C=C32)([H])[C@](CCCC4)([H])[C@]34CC1 |
| Target | Sigma 1 Receptor |
| Signaling Pathway | Neuronal Signaling |
| Solubility | In Vitro: H2O: 10 mg/mL (28.30 mM; Requires sonication and warming and heat to 60°C) DMSO: 1 mg/mL (2.83 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 6 months; -20°C, 1 month. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| H2O | 10 mg/mL (28.30 mM) | requires sonication and warming and heat to 60°C |
| DMSO | 1 mg/mL (2.83 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); avoid repeated freeze-thaw cycles.
If water is used as the stock solvent, dilute to the working solution and sterilize it through a 0.22 μm filter before use.
In Vivo
Choose the formulation that suits the animal model and route of administration. Percentages are volume ratios of the final working solution. Prepare the working solution fresh on the day of dosing; if precipitation or phase separation occurs, gentle warming or sonication can help.
Direct preparation of the working solution
These formulations are prepared directly, without a DMSO stock; use them promptly after preparation.
Protocol 1
| Composition | PBS |
|---|---|
| Result | 16.67 mg/mL (47.17 mM); clear solution; requires sonication and warming and heat to 60°C |
Data provided by the manufacturer.
In Vitro
Dimemorfan (5-20 μM) lowers ROS production triggered by fMLP and by PMA, with concentration dependence, and shows relatively higher potency against the fMLP-triggered response, with an IC50 value of 7.0 μM. Dimemorfan (10-50 μM) shows no significant free radical scavenging activity in the xanthine/xanthine oxidase system. Mac-1 upregulation is significantly suppressed by Dimemorfan in the PMA- and fMLP-activated groups alike. Dimemorfan (10-20 μM) significantly suppresses ROS and NO production induced by LPS, along with LPS-induced iNOS protein expression, and also lowers the percentage of positively stained cells and the MCF intensities of MCP-1 and TNF-α in BV2 cytosol. Dimemorfan (20 μM) significantly blocks degradation of cytosolic Iκ-Bα, nuclear translocation of NF-κB p65, and transcriptional activity of NF-κB[2].
In Vivo
Dimemorfan (6.25 or 12.5 mg/kg, s.c.) significantly reduces BAY k-8644-induced convulsive behaviors, and the effect is dose-related (versus Saline+BAY k-8644: P<0.05 for 6.25 mg/kg dimemorfan+BAY k-8644 and P<0.01 for 12.5 mg/kg dimemorfan+BAY k-8644). Dimemorfan significantly reduces the BAY k-8644-induced rise in c-fos and c-jun protein expression in a dose-dependent manner. In mice, Dimemorfan has no significant effect on locomotor activity and produces no significant circling behavior in any locomotor pattern[1]. Dimemorfan (1 and 5 mg/kg, i.p.) suppresses the rise of plasma TNF-α levels in mice. Treatment with dimemorfan markedly inhibits the LPS-induced neutrophil infiltration into lung and liver and the LPS-induced production of oxidative stress (EB staining) in these tissues[2].
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Animal Administration[1]
Give C57BL/6 mice once a day for 7 days either a morphinan compound (dextromethorphan, dextrorphan, or dimemorfan) at 20 or 40 mg/kg, i.p. per day, or PCP at 2.5 or 5 mg/kg, i.p. per day. Ten minutes after the last treatment with each drug, measure locomotor activity for 30 min with an automated video-tracking system. Operate eight test boxes (40 cm×40 cm×30 cm high) simultaneously from an IBM computer. Study the animals individually during locomotion in each test box, adapting them for 10 min before starting the experiment. Print out each session to show the pattern of ambulatory movements in the test box. Analyze the distance traveled in cm as horizontal locomotor activity. Collect and analyze data between 09:00 and 17:00 h.
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Cyborg Bionic Syst. 2026 Mar 23.
Sigma-1 receptor attenuates osteoclastogenesis by promoting ER-associated degradation of SERCA2. EMBO Mol Med 2022 Jul 7;14(7):e15373. PMID: 35611810
Sigma-1 receptor exerts protective effects on ameliorating nephrolithiasis by modulating endoplasmic reticulum-mitochondrion association and inhibiting endoplasmic reticulum stress-induced apoptosis in renal tubular epithelial cells. Redox Rep 2024 Dec;29(1):2391139. PMID: 39138590
Complutense University of Madrid. 2026.
